
Darolutamide Gains FDA Approval for Metastatic Castration-Sensitive Prostate Cancer
The FDA has approved darolutamide (Nubeqa; Bayer Healthcare Pharmaceuticals) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC), expanding its use beyond previously approved indications.1 This approval is supported …